SU‐FF‐T‐526: Radiobiological Evaluation of Inhomogenity Corrections in Tissue for Lung Cancer Patients

E. Dzintars; P. Mavroidis; S. Stathakis; C. Shi; A. Gutierrez; C. Esquivel; F. Su; N. Papanikolaou

doi:10.1118/1.3182024

SU‐FF‐T‐526: Radiobiological Evaluation of Inhomogenity Corrections in Tissue for Lung Cancer Patients

E. Dzintars, P. Mavroidis, S. Stathakis, C. Shi, A. Gutierrez, C. Esquivel, F. Su, N. Papanikolaou

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To radiobiologically quantify dose difference induced by the inhomogeneity corrections in tissues for lung cancer patients using complication‐free tumor control probability (P₊). Method and Materials: One lung cancer patient was retrospectively selected to quantify the difference in clinical effectiveness due to inhomogeneity correction in treatment planning. Four 3D conformal plans were generated for this patient. These treatment plans include two plans with and without tissue inhomogeneity corrections in tissues using 6 MV photon beams. Also, the other two plans were produced with and without inhomogeneity corrections using 18 MV photon beams. The common prescription for four plans was 40 Gy delivered in 20 fractions. The uniform dose that causes the same tumor control probability or normal tissue complication rate as the actual dose given to the patient was evaluated using the biologically effective uniform dose, BEUD. Results: From physical dose evaluation, the treatment plans without inhomogeneity corrections in tissues had up to 8% lower mean dose estimated in the target. From radiobiological assessment, for the plans generated using 18 MV photon beams, the under‐estimated dose of 1 Gy in the mean dose of the target resulted in 3% lower P₊ in the plans without inhomogeneity corrections. For the plans generated using 6 MV photon beams, the under‐estimated dose of 2 Gy in the mean dose of the target results in 5% lower P₊ in the plans without inhomogeneity corrections. Conclusion: The dose deviation resulting from the lack of inhomogeneity corrections in tissues for lung cancer patients can be quantified into difference in clinical effectiveness using P₊. Treatment plans without inhomogeneity corrections tend to under estimate the P₊. Therefore, treatment plans that have limit access to account for tissue inhomogeneity should be reviewed with caution regarding the accuracy in the physical dose and the resulting clinical outcome of P₊.

Original language	English (US)
Pages (from-to)	2645
Number of pages	1
Journal	Medical physics
Volume	36
Issue number	6
DOIs	https://doi.org/10.1118/1.3182024
State	Published - Jun 2009

ASJC Scopus subject areas

Biophysics
Radiology Nuclear Medicine and imaging

Access to Document

10.1118/1.3182024

Cite this

@article{cf2c295e8cc3401f820a9e1bb66a4aca,

title = "SU‐FF‐T‐526: Radiobiological Evaluation of Inhomogenity Corrections in Tissue for Lung Cancer Patients",

abstract = "Purpose: To radiobiologically quantify dose difference induced by the inhomogeneity corrections in tissues for lung cancer patients using complication‐free tumor control probability (P+). Method and Materials: One lung cancer patient was retrospectively selected to quantify the difference in clinical effectiveness due to inhomogeneity correction in treatment planning. Four 3D conformal plans were generated for this patient. These treatment plans include two plans with and without tissue inhomogeneity corrections in tissues using 6 MV photon beams. Also, the other two plans were produced with and without inhomogeneity corrections using 18 MV photon beams. The common prescription for four plans was 40 Gy delivered in 20 fractions. The uniform dose that causes the same tumor control probability or normal tissue complication rate as the actual dose given to the patient was evaluated using the biologically effective uniform dose, BEUD. Results: From physical dose evaluation, the treatment plans without inhomogeneity corrections in tissues had up to 8% lower mean dose estimated in the target. From radiobiological assessment, for the plans generated using 18 MV photon beams, the under‐estimated dose of 1 Gy in the mean dose of the target resulted in 3% lower P+ in the plans without inhomogeneity corrections. For the plans generated using 6 MV photon beams, the under‐estimated dose of 2 Gy in the mean dose of the target results in 5% lower P+ in the plans without inhomogeneity corrections. Conclusion: The dose deviation resulting from the lack of inhomogeneity corrections in tissues for lung cancer patients can be quantified into difference in clinical effectiveness using P+. Treatment plans without inhomogeneity corrections tend to under estimate the P+. Therefore, treatment plans that have limit access to account for tissue inhomogeneity should be reviewed with caution regarding the accuracy in the physical dose and the resulting clinical outcome of P+.",

author = "E. Dzintars and P. Mavroidis and S. Stathakis and C. Shi and A. Gutierrez and C. Esquivel and F. Su and N. Papanikolaou",

note = "Funding Information: Supported by the American Heart Association and the National Kidney Foundation of Maryland (A.B.); the Polycystic Kidney Research Foundation, the National Institutes of Health (DK48006, DK51042, NIH P50-DK57325), Italian Telethon (A.112), Fondation Alphonse and Jean Fonds de la Recherche Scientifique Medicale and Fonds National de la Recherche Scientifique. G.G.G. is the Blum Scholar of JHU School of Medicine. The investigators are members of the Johns Hopkins Polycystic Kidney Disease Center of Excellence (NIH P50-DK57325). ",

year = "2009",

month = jun,

doi = "10.1118/1.3182024",

language = "English (US)",

volume = "36",

pages = "2645",

journal = "Medical physics",

issn = "0094-2405",

publisher = "AAPM - American Association of Physicists in Medicine",

number = "6",

}

TY - JOUR

T1 - SU‐FF‐T‐526

T2 - Radiobiological Evaluation of Inhomogenity Corrections in Tissue for Lung Cancer Patients

AU - Dzintars, E.

AU - Mavroidis, P.

AU - Stathakis, S.

AU - Shi, C.

AU - Gutierrez, A.

AU - Esquivel, C.

AU - Su, F.

AU - Papanikolaou, N.

N1 - Funding Information: Supported by the American Heart Association and the National Kidney Foundation of Maryland (A.B.); the Polycystic Kidney Research Foundation, the National Institutes of Health (DK48006, DK51042, NIH P50-DK57325), Italian Telethon (A.112), Fondation Alphonse and Jean Fonds de la Recherche Scientifique Medicale and Fonds National de la Recherche Scientifique. G.G.G. is the Blum Scholar of JHU School of Medicine. The investigators are members of the Johns Hopkins Polycystic Kidney Disease Center of Excellence (NIH P50-DK57325).

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: To radiobiologically quantify dose difference induced by the inhomogeneity corrections in tissues for lung cancer patients using complication‐free tumor control probability (P+). Method and Materials: One lung cancer patient was retrospectively selected to quantify the difference in clinical effectiveness due to inhomogeneity correction in treatment planning. Four 3D conformal plans were generated for this patient. These treatment plans include two plans with and without tissue inhomogeneity corrections in tissues using 6 MV photon beams. Also, the other two plans were produced with and without inhomogeneity corrections using 18 MV photon beams. The common prescription for four plans was 40 Gy delivered in 20 fractions. The uniform dose that causes the same tumor control probability or normal tissue complication rate as the actual dose given to the patient was evaluated using the biologically effective uniform dose, BEUD. Results: From physical dose evaluation, the treatment plans without inhomogeneity corrections in tissues had up to 8% lower mean dose estimated in the target. From radiobiological assessment, for the plans generated using 18 MV photon beams, the under‐estimated dose of 1 Gy in the mean dose of the target resulted in 3% lower P+ in the plans without inhomogeneity corrections. For the plans generated using 6 MV photon beams, the under‐estimated dose of 2 Gy in the mean dose of the target results in 5% lower P+ in the plans without inhomogeneity corrections. Conclusion: The dose deviation resulting from the lack of inhomogeneity corrections in tissues for lung cancer patients can be quantified into difference in clinical effectiveness using P+. Treatment plans without inhomogeneity corrections tend to under estimate the P+. Therefore, treatment plans that have limit access to account for tissue inhomogeneity should be reviewed with caution regarding the accuracy in the physical dose and the resulting clinical outcome of P+.

AB - Purpose: To radiobiologically quantify dose difference induced by the inhomogeneity corrections in tissues for lung cancer patients using complication‐free tumor control probability (P+). Method and Materials: One lung cancer patient was retrospectively selected to quantify the difference in clinical effectiveness due to inhomogeneity correction in treatment planning. Four 3D conformal plans were generated for this patient. These treatment plans include two plans with and without tissue inhomogeneity corrections in tissues using 6 MV photon beams. Also, the other two plans were produced with and without inhomogeneity corrections using 18 MV photon beams. The common prescription for four plans was 40 Gy delivered in 20 fractions. The uniform dose that causes the same tumor control probability or normal tissue complication rate as the actual dose given to the patient was evaluated using the biologically effective uniform dose, BEUD. Results: From physical dose evaluation, the treatment plans without inhomogeneity corrections in tissues had up to 8% lower mean dose estimated in the target. From radiobiological assessment, for the plans generated using 18 MV photon beams, the under‐estimated dose of 1 Gy in the mean dose of the target resulted in 3% lower P+ in the plans without inhomogeneity corrections. For the plans generated using 6 MV photon beams, the under‐estimated dose of 2 Gy in the mean dose of the target results in 5% lower P+ in the plans without inhomogeneity corrections. Conclusion: The dose deviation resulting from the lack of inhomogeneity corrections in tissues for lung cancer patients can be quantified into difference in clinical effectiveness using P+. Treatment plans without inhomogeneity corrections tend to under estimate the P+. Therefore, treatment plans that have limit access to account for tissue inhomogeneity should be reviewed with caution regarding the accuracy in the physical dose and the resulting clinical outcome of P+.

UR - http://www.scopus.com/inward/record.url?scp=85024778332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024778332&partnerID=8YFLogxK

U2 - 10.1118/1.3182024

DO - 10.1118/1.3182024

M3 - Article

AN - SCOPUS:85024778332

SN - 0094-2405

VL - 36

SP - 2645

JO - Medical physics

JF - Medical physics

IS - 6

ER -

SU‐FF‐T‐526: Radiobiological Evaluation of Inhomogenity Corrections in Tissue for Lung Cancer Patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this